Baxter International (BAX) Q2 2025 Earnings
How Did BAX Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +1.30%.
Did BAX Beat Earnings? Q2 2025 Results
No. Baxter International reported Q2 2025 earnings of $0.59 a share on Jul 31, 2025, missing the $0.61 consensus estimate by 3.1%. Revenue was $2.8B against a $2.8B estimate.
Baxter International delivered a disappointing second quarter, with adjusted EPS of $0.59 missing the Wall Street consensus of $0.61 by 3.28%, as the lingering aftershocks of Hurricane Helene continued to weigh on results. Revenue of $2.81 billion rose 4.3% year over year, but persistent hospital fluid conservation efforts following last year's storm dampened demand in the Medical Products & Therapies segment, which came in flat at $1.32 billion on a reported basis. The company's shares plunged to their lowest level in nearly two decades following the report, a reaction compounded by Baxter's decision to halt infusion pump shipments and trim its full-year outlook. Management now expects full-year 2025 reported sales growth of 6% to 7% and adjusted diluted EPS of $2.42 to $2.52, a range that explicitly accounts for potential downside risks in Medical Products. For Q3, Baxter guided to adjusted EPS of $0.58 to $0.62, offering investors little immediate relief as the company navigates its post-Helene recovery under incoming CEO Andrew Hider, who takes the helm September 3.
- Strength globally for Advanced Surgery and infusion systems products within Infusion Therapies & Technologies
- Solid global growth for Care & Connectivity Solutions with improvement internationally
- Drug Compounding strength in Pharmaceuticals segment
- IV solutions demand softness due to fluid conservation efforts post-Hurricane Helene partially offset Medical Products & Therapies growth
- Anesthesia sales declined low double digits globally
- Injectables sales declined 1% due to difficult prior-year comparison from timing of a government order
“For the second quarter of 2025, Baxter delivered performance in line with guidance while our employees across the globe continued advancing the company's life-sustaining Mission and building on its vision to redefine healthcare delivery.”
Baxter International CEO, on the earnings call
What Was Baxter International's Outlook in Q2 2025?
For full-year 2025, Baxter now expects sales growth from continuing operations of 6%-7% on a reported basis and 3%-4% operationally. The company expects adjusted diluted EPS of $2.42 to $2.52. The updated guidance attempts to capture potential downside risks primarily impacting the Medical Products & Therapies segment. For Q3 2025, the company expects reported sales growth of 6%-7%, operational sales growth of 3%-4%, and adjusted diluted EPS of $0.58 to $0.62.
BAX YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $2.8B | $2.7B | +4.3% |
| Gross Profit | $991.0M | $1.0B | −3.9% |
| Operating Income | $191.0M | $179.0M | +6.7% |
| Net Income | $122.0M | $51.1M | +138.9% |
BAX Revenue by Segment
BAX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.